Table 3 Efficacy and safety end points of the matched patients.
All (n = 236) | Tirofiban group (n = 118) | Non-tirofiban group (n = 118) | P value | |
|---|---|---|---|---|
Periprocedural complications | ||||
AIST | 9 (3.8) | 1 (0.8) | 8 (6.8) | 0.039 |
Periprocedural ischemic events | 16 (6.8) | 10 (8.5) | 6 (5.1) | 0.424 |
TIA | 0 | 0 | 0 | – |
Ischemic stroke | 16 (6.8) | 10 (8.5) | 6 (5.1) | 0.424 |
Periprocedural ICH | 6 (2.5) | 5 (4.2) | 1 (0.8) | 0.219 |
Systemic bleeding | 0 | 0 | 0 | – |
Post-procedural NIHSS (7d ) | 1 (0,3) | 1 (0,3) | 1 (0,2) | 0.069 |
Follow-up results (30 d) | ||||
Recurrent ischemic events | 0 | 0 | 0 | – |
Recurrent ICH | 0 | 0 | 0 | – |
Total mortality | 4 (1.7) | 4 (3.4) | 0 (0) | 0.125 |
